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Conﬁ  rmed 
Mycoplasma 
pneumoniae 
Endocarditis
To the Editor: In Rosario, Ar-
gentina, during June 2005, a 15-year-
old boy was hospitalized because of a 
2-month history of fever. The patient 
had no history of cardiac disease or in-
travenous drug use. The results of the 
physical examination and the laborato-
ry tests were within normal limits, ex-
cept for an increased leukocyte count 
(14,000/μL) with 68% neutrophils.
Transesophagic echocardiogra-
phy showed mural vegetation on the 
right ventricle (30 mm × 20 mm) with 
no valve involvement. The patient 
was empirically treated with penicil-
lin, gentamicin, and ceftriaxone. After 
treatment failed to produce a response, 
blood was submitted for culture for 
mycobacteria, brucellae, bartonellae, 
molds, and yeasts. BacT/ALERT bot-
tles (bioMérieux, Durham, NC, USA), 
Hemoline performance biphasic me-
dium (bioMérieux, Marcy L’Etoile, 
France), lysis centrifugation, and 
homemade culture broth were used. 
All culture results were negative. Re-
sults of PCR performed on serum for 
Actinobacillus actinomycetemcomi-
tans were also negative. Because only 
the ﬁ  rst samples were obtained before 
antimicrobial drug administration, a 
false-negative result was suspected. 
The patient underwent surgery for 
pulmonary microembolisms, and the 
vegetation was removed 4 weeks after 
drug treatment had started. The histo-
logic appearance of the vegetation was 
consistent with infectious endocarditis, 
but the culture result was negative.
After 6 weeks of treatment, the 
patient was discharged from the hos-
pital; however, 10 days after discharge 
he again became febrile and was read-
mitted to the hospital. The vegetation 
was again found. On this second ad-
mission, all cultures were performed 
before administration of antimicrobial 
drugs, and several types of culture me-
dia were used. In the absence of any 
growth by day 6, the patient’s serum 
was screened for antibodies to Myco-
plasma pneumoniae, Chlamydia pneu-
moniae, and Bartonella henselae. Se-
rologic tests for immunoglobulin (Ig) 
G and IgM were conducted by indirect 
immunoﬂ  uorescence  assay  (slides 
from Bion; Des Plaines, IL, USA) and 
ﬂ   uorescein-labeled anti-human IgG 
and IgM (bioMérieux). For the IgM 
assay, the serum was pretreated with 
IgG/RF stripper (The Binding Site 
Ltd., Birmingham, UK). The titers for 
M. pneumoniae IgG and IgM antibod-
ies were 2,048 and 160, respectively. 
Blood cultures were then subcultured 
in homemade Hayﬂ  ick medium. These 
samples were incubated in 5% CO2 in a 
37°C incubator and examined 2×/week 
for typical M. pneumoniae colonies.
After 9 days of incubation, Hay-
ﬂ  ick agar plates inoculated with ali-
quots taken from homemade blood 
culture bottles (beef extract 5 g, yeast 
extract 5 g, peptone 10 g, glucose 2 
g, NaCl 5 g, Na2HPO4 2.5 g, sodium 
heparin 10,000 U, distilled water to 
1,000 mL, pH 7.6) showed colonies 
consistent with M. pneumoniae. No 
isolates were recovered from commer-
cial blood culture bottles.
Result of hemolysis test with 
sheep blood was positive. The iso-
late was deﬁ  nitively identiﬁ  ed as M. 
pneumoniae after P1 cytadhesin gene 
ampliﬁ   cation by nested PCR, with 
primers P1-40, P1-178, P1-285, and 
P1-331 (1).
After mycoplasma were was iso-
lated, intravenous clarithromycin was 
added to ceftriaxone; the ceftriaxone 
was discontinued 1 week later. The 
patient’s clinical condition improved, 
and he was discharged 3 weeks after 
bacteriologic diagnosis with a treat-
ment regimen of oral levoﬂ  oxacin. 
After 6 months of treatment, the veg-
etation was reduced with no evidence 
of calciﬁ  cation.
Mycoplasma  spp. have rarely 
been associated with endocarditis; un-
til 2007, reports of only 8 cases had 
been published (2–8). The patient de-
scribed herein had no underlying med-
ical problems or immunodeﬁ  ciency. 
Results of lymphocyte subsets, immu-
noglobulin titers, response to tetanus 
toxoid, and pneumococcal capsular 
polysaccharide were within reference 
ranges.
Cases of culture-negative endo-
carditis are not routinely investigated 
for mycoplasmas; however, the role 
of these microorganisms as a cause of 
endocarditis might be underestimated. 
Mycoplasma spp. cannot be detected 
by Gram stain and are difﬁ  cult to iso-
late in bacteriologic culture media. 
Commercial blood culture broths that 
use sodium polyanetholsulfonate as 
an anticlotting agent are not suitable 
for growing these microorganisms 
(9). Other diagnostic approaches in-
clude the detection of speciﬁ  c DNA 
sequences or the use of broad-range 
eubacterial primers in cardiac tissue 
(6). In the patient reported here, the 
clinical sample (vegetation) was not 
available for diagnostic M. pneumo-
niae gene ampliﬁ  cation. We failed to 
detect M. pneumoniae by PCR-medi-
ated gene ampliﬁ  cation directly from 
whole blood and plasma. Theoretical-
ly, speciﬁ  c PCR should be more sensi-
tive than culture, as shown in respira-
tory specimens, but to date attempts 
to detect M. pneumoniae in blood by 
PCR have not been successful. The 
bacterial load in blood may have been 
too low to detect the ampliﬁ  ed prod-
uct by ethidium bromide–stained gel 
electrophoresis. The larger volume 
of blood used and the preincubation 
in broth with yeast extract for 7 days 
could have improved the recovery 
by culture. Another cause of reduced 
PCR sensitivity may have been the use 
of frozen samples.
This case of endocarditis caused 
by  M. pneumoniae was conﬁ  rmed 
by culture and occurred in a patient 
with no previous heart disease. Fur-
ther studies are needed to evaluate the 
real incidence of M. pneumoniae as 
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a cause of endocarditis as well as the 
occurrence of mycoplasma bacteremia 
in the absence of underlying infection 
of the endocardium.
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Human Rhinovirus 
Group C Infection 
in Children with 
Lower Respiratory 
Tract Infection
To the Editor: Human rhinovi-
ruses (HRVs), members of the family 
Picornaviridae, were ﬁ  rst isolated in 
1956 (1); to date, >100 serotypes have 
been identiﬁ  ed on the basis of nucle-
otide sequence homologies. HRVs 
were previously divided into 2 genetic 
groups, HRV-A (n = 75) and HRV-B 
(n = 25). Recently, a putative new and 
distinct rhinovirus group, HRV-C, has 
been reportedly found in some patients 
with respiratory tract infections (RTIs) 
(2–8). To extend these initial ﬁ  ndings 
and assess the pathogenicity of HRV-C, 
we investigated its prevalence as well 
as its clinical and molecular features 
in children with lower acute RTIs in 
Beijing, People’s Republic of China.
From July through December 
2007, nasopharyngeal aspirates were 
collected from 258 children (167 boys 
and 91 girls) who had lower acute 
RTIs at the time of their admission 
to Beijing Children’s Hospital. The 
children were 1 month to 15 years 
of age (mean age 37 months, median 
age 10 months). Nucleic acids were 
extracted from clinical samples by us-
ing the NucliSens easyMAG platform 
(bioMérieux SA, Marcy L’Etoile, 
France). Each specimen was tested for 
the presence of common respiratory 
viruses: human parainﬂ  uenza viruses 
1–4, inﬂ   uenza viruses, respiratory 
syncytial virus, enteroviruses, human 
coronaviruses (229E, NL63, HKU1, 
and OC43), metapneumovirus, adeno-
viruses, and bocaviruses. To study the 
prevalence of HRV-C, we designed 
a speciﬁ   c reverse transcription–PCR 
(RT-PCR) that generated a 330-bp 
PCR product encompassing a portion 
of the 5′-untranslated region, the full 
virus capsid protein (VP) 4 gene, and a 
portion of the VP2 gene of the HRV-C 
genome. (All primer sequences and 
protocols of these assays are available 
from J.W. upon request.)
This RT-PCR detected HRV-C 
in 14 patients (12 boys and 2 girls, 1 
month to 13 years of age [mean age 
19 months, median age 6 months]). In 
6 of the 14 patients, HRV-C was the 
only virus detected, which suggests 
a direct correlation between HRV-C 
infection and lower acute RTIs. In the 
remaining 8 patients, other respiratory 
viruses were also detected. Respirato-
ry syncytial virus, the most important 
cause of lower acute RTIs in children, 
was codetected in 7 of the HRV-C–
positive patients, and human parain-
ﬂ  uenza virus 3 was codetected in the 
other patient. Human coronavirus 
NL63 was codetected with respiratory 
syncytial virus in 1 HRV-C–positive 
patient. 
HRV-C infection may be season-
al. This virus was detected during only 
3 of the 6 months in which specimens 
were collected. Speciﬁ  cally,  HRV-C 
was detected in samples collected in 
October (7/50), November (5/96), and 
December (2/8) but not in those col-
lected in July (0/37), August (0/42), 
or September (0/25). In contrast, 
HRV-A and HRV-B were detected in 
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